Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Clinical Trial
61%
Programmed Death-Ligand 1
57%
Thymic Carcinoma
52%
Thymus Cancer
52%
Recurrent Disease
47%
Neoplasm
45%
Neoadjuvant Immunotherapy
41%
Hepatocellular Carcinoma
41%
Liver Fibrosis
41%
Lung Tumor
41%
Epidermal Growth Factor Receptor Kinase Inhibitor
41%
Lymphocyte
41%
Paclitaxel
41%
Cetuximab
41%
Neoadjuvant Chemotherapy
41%
Transthoracic Biopsy
41%
Cisplatin
41%
Programmed Cell Death
41%
Computer Assisted Tomography
41%
Lung Cancer
41%
Cell Transformation
41%
Epithelioma
41%
Mouth Squamous Cell Carcinoma
41%
Crizotinib
41%
Epidermal Growth Factor Receptor
37%
Multivariate Analysis
29%
Neoadjuvant Therapy
25%
Progression Free Survival
24%
Biopsy Technique
22%
Logistic Regression Analysis
20%
Lung Nodule
20%
Personalized Medicine
20%
Diagnostic Accuracy
20%
Ground Glass Opacity
20%
Overall Survival
18%
Two-Photon Microscopy
17%
Exon
17%
Fluorescence Microscopy
17%
Tyrosine-Kinase Inhibitor
16%
Proportional Hazards Model
16%
Adipophilin
14%
Non-Small Cell Lung Cancer
11%
Gefitinib
11%
Magnetic Resonance Imaging
11%
Programmed Cell Death
11%
Disease Free Survival
11%
Mediastinal Lymph Node
8%
Oral Cavity
8%
Tumor Biopsy
8%
Biochemistry, Genetics and Molecular Biology
STAT3
47%
Tyrosine Kinase Inhibitor
41%
Two-Photon Microscopy
41%
Receptor Tyrosine Kinase Inhibitors
41%
Epidermal Growth Factor Receptor
41%
Artificial Intelligence
41%
Cell Death
41%
Glycosylation
41%
Fluorescence Microscopy
41%
SOX2
20%
Morphology
13%
Overall Survival
13%
Alpha-Fetoprotein
13%
Disease Free Survival
13%
Programmed Cell Death
11%
Progression Free Survival
11%
Gefitinib
11%
Small Hairpin RNA
10%
Drug Resistance
10%
Cancer Cell
10%
Gene Expression
10%
Dynamics
10%
Glycosyltransferase
10%
Mesenchymal-Epithelial Transition
10%
Cell Function
10%
Transcriptome
10%
Prospective Study
5%
Protein Kinase B
5%
Carcinogenesis
5%
Keyphrases
Transthoracic Needle Biopsy
41%
Biochemotherapy
41%
Cytoplasmic Lipid Droplet
41%
Volume Fraction Estimation
41%
Small Cell Transformation
41%
Crizotinib-resistant
41%
ROS1 Fusion
41%
Thymectomy
36%
Two-photon Excitation Fluorescence Microscopy
24%
Prefire
20%
Major Pathological Response
17%
Adipophilin
16%
Good's Syndrome
15%
Transcriptome Expression
13%
YAP Activation
13%
Glycosyltransferase Genes
13%
CT Slice Thickness
10%
Dermatological Complications
8%
Best Overall Response
8%
EHHADH
8%
CD96
8%
C-ros Oncogene 1
6%
Plasmablastic
5%
B-cell Clonality
5%
Extracavitary
5%
Quantitative MRI
5%
WHO Histological Classification
5%
MRI T1 Mapping
5%
Parametric Mapping
5%
EGFR Exon 20 Insertion
5%
Preoperative Biopsy
5%
MET Exon 14
5%
Advanced Stage NSCLC
5%
Autoimmune Hemolytic Anemia
5%
Secondary Autoimmune Disease
5%
